Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial

(2010) Maria-Victoria Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Mighty mouse

(2009) A. J. Johnson   BLOOD

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

(2009) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

(2009) Cyrille Hulin et al.   JOURNAL OF CLINICAL ONCOLOGY

Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Heparan sulfate proteoglycans, Fc receptors, and DC suppression

(2008) E. Roosnek et al.   BLOOD

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

(2008) A. Palumbo et al.   BLOOD

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

(2008) A. A. Argyriou et al.   BLOOD

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE